Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    Intraperitoneal (IP) chemotherapy for metastatic ovarian cancer
    Ovarian cancer

    Effective Treatment for Ovarian Cancer Is Underused

    A new study reported in the Journal of Clinical Oncology has shown that fewer than half of women with metastatic ovarian cancer are receiving an effective treatment that could improve ovarian cancer outcomes.
    October 13, 2015
    Adverse events

    Antiemetics for Nausea and Vomiting Simplified

    As oncology nurses, we must have a solid understanding of and a certain comfort level with the use of antiemetics. It seems easy to get stuck in a routine that revolves around one or two drugs for all of our patients. However, antiemetic regimens need to be just as individualized for patients as their chemotherapy regimens.
    July 14, 2015
    Cancer treatments

    Understand Medication Adherence to Oral Oncology Agents

    More than half of new cancer treatment regimens involve an oral route of administration because oral drugs are more manageable and convenient for patients. However, oral medications pose challenges with regard to patient adherence.
    April 25, 2015
    Chemotherapy

    Outpatient Oncology Drug Series: Doxorubicin Is the Infamous Red Devil

    Doxorubicin is a cytotoxic chemotherapy drug and an antitumor antibiotic in the anthracycline group. You’ll see this drug quite a lot In the outpatient setting, and most commonly, you’ll use it to treat patients with breast cancer.
    April 10, 2015
    Cancer treatments

    Outpatient Oncology Drug Series: Don't Forget Leucovorin Calcium, the Superhero Sidekick

    I think it's helpful to be able to educate your patients on the reasons for receiving each individual drug in a combination regimen. Although leucovorin is not a chemotherapy agent or generally used as a stand-alone drug, it certainly is important. Leucovorin has a specific function, and you should be able to explain its purpose.
    March 16, 2015
    Appetite stimulants for unintended weight loss
    Cancer treatments

    When Should Appetite Stimulants Be Discussed With Patients With Unintended Weight Loss From Cancer Treatment?

    Unintended weight loss and anorexia in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life.
    January 20, 2015
    Chemotherapy

    Outpatient Oncology Drug Series: Paclitaxel Packs a Punch

    Oncology nursing is a field in which you are challenged on a regular basis to expand your knowledge because of the constantly changing field of treatments being used. Whether you are new or seasoned, it can be difficult to stay on top of the numerous agents used for varying diagnoses.
    December 12, 2014
    Medical Cannabis for cancer
    Adverse events

    The Case of the Cannabis Conundrum

    Derek is a 20-year-old patient with relapsed acute myeloid leukemia. He will be receiving a bone marrow transplant in the next six days. When discussing Derek’s home medications, he says to the nurse, “I smoke a lot of pot because it helps me feel better about all of this.” Upon further discussion, Derek reveals he started smoking marijuana to relieve nausea. What would you do?
    December 02, 2014
    Immune-realted adverse events
    Adverse events

    Manage Immune-Related Adverse Events Associated With Cancer Immunotherapies

    The FDA approved two new immunomodulatory agents, sipuleucel-T and ipilimumab, in 2010 and 2011, respectively. Sipuleucel-T was approved to treat metastatic prostate cancer, and ipilimumab was approved for advanced or metastatic melanoma.
    September 09, 2014
    Oncology genetics key definitions
    Genetics & genomics

    Get a Cheat Sheet on Personalized Medicine, Genomics, and Pharmacogenomics in Oncology

    Since the concepts of inheritance, genetics, and medical genetics were introduced, researchers have found that many factors other than the presence or absence of a single gene predict disease.
    August 12, 2014
    Benefits of palliative chemotherapy
    Chemotherapy

    Balance Harms and Benefits of Palliative Chemotherapy at End of Life

    The American Society of Clinical Oncology recently identified end-of-life chemotherapy as one of the top-five practices that could improve patients’ care and reduce costs, if stopped.
    May 20, 2014
    Oncology drug research

    FDA Approves Ramucirumab for Gastric or Gastroesophageal Junction Adenocarcinoma

    On April 21, 2014, the U.S. Food and Drug Administration approved ramucirumab for use as a single agent for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.
    April 22, 2014
    Oral chemotherapy administration safety
    Chemotherapy

    U.S. Survey Reports Oral Chemotherapy Practice and Safety Patterns

    As chemotherapy administration has shifted from IV delivery in the infusion center to oral delivery at home, so has the burden for the five rights of medication administration.
    March 11, 2014
    Understanding safe handling of oral agents
    Oral adherence

    No Ordinary Pill

    Oral agents are changing oncology treatment, and along with it, who’s responsible for the safety of those treatments. “With oral agents, the onus is now primarily on patients and their caregivers,” says ONS member Kathy Leifeste. This is quite a shift from the nurse-administered IV chemotherapy and biotherapy we’ve grown accustomed to.
    March 01, 2014
    New hematology-related evidence-based recommendations
    Cancer treatments

    ASH Recommends Wise Choices for Five Hematologic Tests and Treatments

    A new list of evidence-based recommendations from the American Society of Hematology helps patients and providers understand which hematology-related tests and treatments pose significant harm and cost if overused and therefore should be avoided.
    February 18, 2014
    Targeted therapy

    The Names of Targeted Therapies Give Clues to How They Work

    I was reading through the program of my granddaughter's dance recital and noticed that there was not a single common name in the first three groups of young dancers. It was as if their parents purposefully decided to come up with the most unique names possible. This is not the case with the family names of targeted cancer drugs.
    December 31, 2013
    HCT recipients and post-treatment care
    Access to cancer care

    Help Rural HCT Recipients Overcome Barriers to Post-Treatment Care

    For patients with hematologic malignancies and genetic immune disorders, HCT is a potentially curative treatment. However, because the therapy is so specialized, only select cancer centers with the appropriate expertise, resources, and experiences offer it.
    September 10, 2013
    Promising new oncology drugs
    Cancer treatments

    Several Promising New Cancer Drugs Could Come to Market by 2015

    Many promising studies presented at the 2013 American Society of Clinical Oncology annual meeting involved new cancer drugs that empower the body’s defense system.
    August 27, 2013
    Melanoma

    FDA Approves Dabrafenib for Unresectable or Metastatic Melanoma

    On May 29, 2013, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar™ capsule, GlaxoSmithKline), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    May 30, 2013
    Treatment side effects

    Veno-Occlusive Disease Is the Most Common Hepatic Complication in Stem Cell Transplants

    Autologous transplantation: patients receive their own stem cells after a course of myeloablative conditioning
    November 02, 2012
    Chemotherapy

    Find Out How Simulation Is Used in Chemotherapy Education and Competency Measurement

    As the range of diag­noses on medical-​​surgical units becomes more com­plex
    May 20, 2012
    Cancer treatments

    ONS Clinical Lectureship Recipient Talks About New Treatment Options for Renal Cancer

    Since 2005, seven new targeted therapies have been approved for renal cell carcinoma
    May 02, 2012
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Current page 6
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲